Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

Mini Review - (2023) Volume 11, Issue 1

Nerve Tumours

Isabelle Michael*
Medical Faculty Heidelberg, University of Heidelberg, Germany
*Correspondence: Isabelle Michael, Medical Faculty Heidelberg, University of Heidelberg, Germany, Email:

Received: 02-Jan-2023, Manuscript No. ipacr-23-13408; Editor assigned: 04-Jan-2023, Pre QC No. ipacr-23-13408 (PQ); Reviewed: 18-Jan-2023, QC No. ipacr-23-13408; Revised: 23-Jan-2023, Manuscript No. ipacr-23-13408 (R); Published: 30-Jan-2023, DOI: 10.36648/2254-6081-11.1-105


Peripheral nerves, the nerves that branch out from the brain and spinal cord and go through the rest of the body, are home to abnormal lumps known as nerve tumours. The nerve sheath, or protective coating, and supporting tissue are where nerve tumours grow. Most are good. However, because they can push on nerves and result in discomfort, nerve damage, and/or loss of function, even some noncancerous tumours need to be treated. Depending on the nature, nerve tumours can develop slowly or swiftly. Some people merely require monitoring and don't require any therapy. Rarely, malignant nerve tumours require aggressive therapy.


Malignant peripheral nerve sheath tumor; Neurilemmoma; Neurofibroma; Neurofibromatosis; Schwannoma


Growths that develop in or close to nerves are called peripheral nerve tumours. The tissue strands known as nerves are responsible for carrying information from the brain to the rest of the body. The muscles that allow you to move, blink, swallow, pick things up, and do other tasks are controlled by peripheral nerves. Anywhere in the body might develop peripheral nerve tumours. The majority of them are benign, or non-cancerous. However, they can cause discomfort, harm to the nearby nerves, and loss of functionality. Surgery to remove the tumour is frequently required for treatment. Other therapies could be attempted if the tumour cannot be removed without harming the adjacent healthy tissue and nerves. Peripheral nerve tumours come in a variety of forms. An intraneural tumour develops inside a nerve. Nerves are pressed upon by extraneural malignancies [1-4].

Your peripheral nerves connect your spinal cord, brain, and other body components. These nerves regulate the muscles in your body, allowing you to walk, blink, swallow, pick things up, and do other actions. Peripheral nerves may develop a variety of tumour forms. Typically, there is no recognised aetiology for these tumours. Some are caused by genetics. The majority of these tumours are not malignant (benign). However, they can cause muscular control loss and nerve damage. This is why it's crucial to visit your doctor if you have any strange lumps, discomfort, tingling or numbness, or muscular weakness [5-8].

Benign peripheral nerve sheath tumours (BPNSTs) and malignant peripheral nerve sheath tumours are two types of nerve tumours of the upper extremities (MPNSTs). Schwannomas, which are benign tumours derived from Schwann cells, are the most prevalent peripheral nerve sheath tumours (PNSTs) of the hand and upper extremity. In schwannomatosis, several schwannomas may develop. Although they can develop as isolated lesions, benign neurofibromas can also be associated with neurofibromatosis (NF). The underlying anatomy's gigantism may also be linked to these malignancies. By carefully dissecting the intrafascicular tissue under a microscope, BPNSTs can be surgically removed or seen. BPNSTs have the potential to develop into MPNSTs, which call for more aggressive surgical care from a multidisciplinary team. It is addressed how to distinguish malignant tumours from their benign counterparts using clinical and radiological features. The most recent suggested additionally, a review of surgical methods for tumour excision is done.


Schwannoma: Schwannomas are the most prevalent benign peripheral nerve tumour in adults and can develop practically anywhere on the body. Because Schwann cells, which are cells that surround the nerves, are present in these nerve sheath tumours, they are known as schwannomas. Typically, these tumours develop slowly. You could feel a mass if you acquire a schwannoma in your arm or leg. However, you might have a schwannoma for years without realising it. Typically, a fascicle, or solitary bundle of nerve fibres within the main nerve, is the source of a schwannoma. Some schwannomas develop and take on peculiar forms like dumbbell tumours in the spine or pelvis. When removing a schwannoma successfully, more fascicles are at danger as the tumour develops. Schwannomas often develop on their own. Many of them can occasionally be found in the arms, legs, or body of certain persons. The medical term for this is schwannomatosis. Acoustic neuroma, an uncommon schwannoma close to the brainstem, can impair balance or hearing. The term vestibular schwannoma is another name for this kind of tumour. Neurofibromatosis 2 patients might occasionally experience it (NF2). Acoustic neuromas can harm neighbouring nerves and encroach on the brainstem if they are left untreated and develop further.

Neurofibroma: This typical kind of benign nerve tumour usually develops in the nerve's middle. Multiple nerve bundles may give birth to a neurofibroma, which often has modest symptoms. The majority of individuals with this tumour have neurofibromatosis type 1. (NF1). This hereditary condition results in tumours developing on the nerves. Color changes and skin lesions that are benign are NF1 symptoms. Some persons with NF1 go on to acquire additional illnesses. These ailments include visual nerve tumours known as optic gliomas and bone abnormalities like a bent spine. Malignant peripheral nerve sheath tumours can arise in people with NF1.

Perineurioma: Perineurial cells, a specific type of cell that encircles the peripheral nerve sheath, give birth to this uncommon benign peripheral nerve tumour. A perineurioma known as an intraneural perineurioma can develop inside a nerve. A soft tissue growth termed an extraneural perineurioma may also develop adjacent to a nerve. The majority of intraneural perineuriomas affect children and young adults. Typically, it results in a weakening and numbing of an arm or leg over time.

Lipoma: This benign, soft lump commonly develops beneath the skin on the neck, shoulders, back, or arms due to slow-growing fat cells. A nerve may be compressed by a lipoma nearby. However, a lipoma often doesn't cause any discomfort or other issues. Your doctor may recommend frequent exams to keep an eye on a lipoma.

Glioma cyst: While some ganglion cysts are caused by injuries, the majority have no known origin. They frequently develop close to joints, such the wrist, and can hurt and hinder with daily tasks. Some ganglion cysts fade away on their own, but those that impinge on nearby nerves need to be removed.

Therapeutic Presentation

Rapid development, pain at night, size greater than 5 cm, formerly soft consistency that turns firm and any concomitant constitutional symptoms are all hallmarks of MPNST malignancy. For schwannomas, malignant transformation is uncommon. Compared to isolated lesions, neurofibromas connected to NF are more likely to develop malignant transformation. NF1 patients may experience MPNSTs at a rate of 2% to 13% compared to 0.001% of the general population. 5, 6; 50% of MPNSTs in NF1 patients can develop postradiation or incidentally. A plexiform neurofibroma's rapid development in NF1 may not signify malignant change. This clinical discovery is currently being thoroughly researched. An MPNST-positive family history, according to a recent study on the effects of family history is a risk factor for the emergence of MPNST at a younger age in individuals with NF1.9.

A firm, slowly expanding mass that is either asymptomatic or radiates pain or paresthesia along the course of the nerve is the typical clinical presentation of benign tumours. Physical examination may reveal a positive Tinel sign over the bulk [9-10].


Since nerve sheath tumours are very uncommon, patients should seek advice from a specialist who regularly handles patients with this diagnosis and is knowledgeable with the possible drawbacks and advantages of various treatment approaches. The majority of benign nerve sheath tumours just require surveillance, which entails periodic imaging and follow-up physical exams. Surgery is used to treat certain nerve sheath cancers. Radiation, chemotherapy, and surgery are a few possible treatments for malignant peripheral nerve sheath tumours. Since there is a chance of nerve injury with surgical therapy, it is crucial to trust experienced surgeons if a patient needs surgery for a nerve sheath tumour. In order to maximise safety and provide patients the best opportunity for success, the surgeon may use electromyography or evoked potentials to monitor nerve function during surgery.

Our findings revealed that MPNSTs superficial to the fascia are exceedingly rare and that bigger tumours are more likely to be malignant, despite the fact that we could not identify a clinically significant size threshold. Diagnostically speaking, metabolic data were quite precise and similar. Although the limitations of their predictive abilities should be appreciated and taken into account, clinical symptoms may also be useful. Last but not least, necrosis could be a useful and as of yet underappreciated predictor of malignancy.


  1. Saro HA, Christopher JG, Russell CR, Kirsten KN (2019) Premature aging in young cancer survivors. J Natl Cancer Inst111: 226-232.
  2. Indexed at, Google Scholar, Crossref

  3. Addie H, Jaya S, Mark AL, Arti H (2020) How cancer therapeutics cause accelerated aging: insights from the hallmarks of aging. J Geriatr Oncol11: 191-193.
  4. Indexed at, Google Scholar, Crossref

  5. Jens HW, Karl FH, Mario PS, Andrea H, Bernd K et al. (2008) Hypertension induces somatic cellular senescence in rats and humans by induction of cell cycle inhibitor p16INK4a. Hypertension52:123-129.
  6. Indexed at, Google Scholar, Crossref

  7. Julie W, Anna KU, Johannes R, Nichola F, Lauren B et al. (2015) Vascular smooth muscle cell senescence promotes atherosclerosis and features of plaque vulnerability. Circulation 132: 1909-1919.
  8. Indexed at, Google Scholar, Crossref

  9. Impreet K, Preety R, Sumati R, Mohsin HB, Priyanka S et al. (2018) Endothelial progenitor cells from aged subjects display decreased expression of sirtuin 1, angiogenic functions, and increased senescence. Cell Biol Int42: 1212-1220.
  10. Indexed at, Google Scholar, Crossref

  11. Thomas K, Chrysiis M, Wolter JM, Daniel SP (2010) The essence of senescence. Genes Dev24: 2463-2479.
  12. Indexed at, Google Scholar, Crossref

  13. Tareq S, Liliya Tyutyunyk M, Graeme FM, Moureq RA, Ajinkya SK et al. (2019) Tumor cell escape from therapy-induced senescence. Biochem Pharmacol162: 202-212.
  14. Indexed at, Google Scholar, Crossref

  15. Campisi J, Kim SH, Lim CS, Rubio M (2001) Cellular senescence, cancer and aging: the telomere connection. Exp Geronto,36: 1619-1637.
  16. Indexed at, Google Scholar, Crossref

  17. Darren JB, Tobias W, Tamar T, Nathan KL, Bennett G C et al. (2011) Clearance of p16 Ink4a-positive senescent cells delays ageing-associated disorders. Nature479: 232-236.
  18. Indexed at, Google Scholar, Crossref

  19. Tyler JB, Asef A, Charlton FM, Barbara LS, Deursen M J et al. (2018) Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature562:578-582.
  20. Indexed at, Google Scholar, Crossref

Citation: Michael I (2023) Nerve Tumours. Archives Can Res, Vol.11 No. 1: 105.